05/11/2017

The FDA has approved KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin for the first-line treatment of metastatic nonsquamous NSCLC.

The FDA has approved KEYTRUDA^® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta^®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. Under the FDA’s accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

For more information, click here.